The optimal role for targeting FLT3 may depend on multimodality therapy and will likely
require hematopoietic transplant. The incorporation of ABL kinase inhibitors into acute …

FLT3 inhibition has been a goal of acute myeloid leukemia (AML) therapy since FLT3
mutations were discovered to have a role in AML. Several FLT3 inhibitors have been …

Mutations in the fms-like tyrosine kinase 3 (FLT3) gene are detected in approximately one-
third of patients with newly diagnosed acute myeloid leukemia (AML). These consist of the …

FLT3 inhibition as a targeted therapy for acute myeloid leuk... : Current Opinion in Oncology
FLT3 inhibition as a targeted therapy for acute myeloid leukemia : Current Opinion in Oncology …

Internal tandem duplications and tyrosine kinase mutations in the fms-like tyrosine kinase 3
(FLT3) receptor can occur in acute myeloid leukemia (AML) and portend a poor prognosis …

Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are detected in approximately 30%
of acute myeloid leukemia (AML). The high frequency of FLT3 mutations, along with their …

Despite recent modest improvements in the chemotherapy regimens used to treat acute
myeloid leukemia (AML), many patients diagnosed with AML ultimately die of the disease …

Acute myeloid leukemia (AML) is an aggressive hematopoietic malignancy that is cured in
as few as 15%–40% of cases. Tremendous improvements in AML prognostication arose …

The receptor tyrosine kinase fms-like tyrosine kinase 3 (FLT3), involved in regulating
survival, proliferation, and differentiation of hematopoietic stem/progenitor cells, is …

Abstract Learning Objectives After completing this course, the reader will be able to:
Incorporate FLT3 mutational status into the initial diagnostic evaluation of AML to acquire …